Maria Lazou is a Ph.D. candidate in the Department of Biomedical Engineering at Boston University. She earned her bachelor's degree in Biomedical Engineering from Boston University. Her research interests focus on modeling biomolecular systems, with an emphasis on molecular interactions. Her work also involves combining physics-based approaches with machine learning.

Ayse A. Bekar-Cesaretli is a PhD candidate in the Department of Chemistry at Boston University. She holds her undergraduate degree in Chemistry from Bogazici University. Her graduate-level work focuses on computational druggability evaluations using binding hot spot mapping. She also is involved in the methods development of automated druggabilility evaluation pipelines that leverage properties of binding hot spots.

Sandor Vajda is a professor of biomedical engineering and chemistry at Boston University. He received his MSc in applied mathematics and PhD in chemistry in Budapest, Hungary. He has held research positions in the Department of Engineering, University of Warwick, and the Department of Chemistry, Princeton University. He has been active in method development for modeling of biological macromolecules, with a focus on the analysis of protein–protein interactions, the characterization of protein-binding sites, target identification, druggability assessment, and the development of computational methods for fragment-based drug discovery. His group developed the protein–protein docking program and server ClusPro andvthe FTMap family of protein-mapping servers for the identification of binding hot spots.

Diane Joseph-McCarthy is the Executive Director of the Bioengineering Technology & Entrepreneurship Center and Professor of the Practice in Biomedical Engineering and Chemistry at Boston University. Prior to that, she was a life science executive with over 20 years of drug discovery, development, and leadership experience. She was Senior Vice President of Discovery and Early Development at EnBiotix, a bioengineering company focused on respiratory and rare diseases. She was also an Associate Director at AstraZeneca, where she led a global team in Predictive Science. At Wyeth, she held positions of increasing responsibility. Diane received her PhD from MIT and was a postdoctoral fellow at Harvard University/Harvard Medical School. She is a fellow of the American Institute for Medical and Biological Engineering.